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Vomocytosis, or nonlytic extrusion, is a poorly understood process through which macrophages release live
pathogens that they have failed to kill back into the extracellular environment. Vomocytosis is conserved across
vertebrates and occurs with a diverse range of pathogens, but to date, the host signaling events that underpin
expulsion remain entirely unknown. We use a targeted inhibitor screen to identify the MAP kinase ERK5 as a
critical suppressor of vomocytosis. Pharmacological inhibition or genetic manipulation of ERK5 activity significantly
raises vomocytosis rates in human macrophages, whereas stimulation of the ERK5 signaling pathway inhibits
vomocytosis. Lastly, using a zebrafish model of cryptococcal disease, we show that reducing ERK5 activity in vivo
stimulates vomocytosis and results in reduced dissemination of infection. ERK5 therefore represents the first
host signaling regulator of vomocytosis to be identified and a potential target for the future development of
vomocytosis-modulating therapies.INTRODUCTION
Phagocytes are an essential component of the innate immune system,
which function to identify, engulf, and destroy foreign particles. Al-
though the vast majority of microbes are readily killed by phagocytes
upon internalization, a number of important human pathogens have
evolved mechanisms to survive or replicate within this hostile host
environment. Phagocytes infected with these organisms have one of
two fates: either they successfully recognize and destroy the intracellular
pathogen or the pathogen lyses and kills the host cell.More than 10 years
ago, we and others discovered a third potential outcome, whereby host
macrophages expel the live pathogen residing within it in a process
known as vomocytosis or nonlytic extrusion (1, 2). Vomocytosis has
subsequently been observed with a diverse range of pathogens (3) and
in phagocytic cells from mammals (4), birds (5), fish (6), and amoebae
(7), suggesting that it is an evolutionarily conserved phenomenon.How-
ever, despite this marked conservation, the host molecules that regulate
vomocytosis have remained enigmatic.RESULTS
To begin addressing the underlying molecular pathways that regulate
vomocytosis, we screened a library of inhibitors that target kinases
known to be expressed inmacrophages (table S1) (8). This initial screen
identified one compound [LRRK2-IN-1 (9)] that showed a small butsignificant increase in vomocytosis rates without enhancing cell death.
LRRK2-IN-1 inhibits the leucine-rich repeat kinase LRRK2 but has ad-
ditionally been demonstrated to act against other kinases, including the
bromodomain protein BRD4 (10) and the extracellular receptor kinase
5 (ERK5) (11). Testing an independent second series of inhibitors
revealed a potent and reproducible enhancement of vomocytosis
with the ERK5 inhibitors XMD17-109 (12) or AX15836, but not with
a specific inhibitor of BRD4 [JQ1 (13)] or with an alternative inhibitor
of LRRK2 [HG1010201 (14)] (Fig. 1A and table S1). Notably, direct ex-
posure of cryptococci to ERK5 inhibitors in vitro did not alter fungal
morphology or growth rate (fig. S1), indicating that the impact of
ERK5 inhibition on vomocytosis acts at the level of the host macro-
phage and not of the pathogen itself. In addition, exposing cells to
LRRK2-IN-1 and XMD17-109 together did not enhance vomocytosis
levels beyond that of XMD17-109 alone, suggesting that it is the off-
target inhibition of ERK5 by LRRK2-IN-1 that accounts for its effect
on vomocytosis.
To confirm this role for ERK5 in enhancing vomocytosis, we first
exposed human macrophages, differentiated from peripheral blood
monocytes, to XMD17-109. It has previously been shown that primary
human macrophages show higher basal rates of vomocytosis than
phagocytic cell lines (2), but nevertheless, as with J774 cells (which
are originally derived from mouse), human macrophages showed a
significant increase in vomocytosis when ERK5 activity was inhibited
(Fig. 1B). Second, we tested the role of ERK5 in vomocytosis directly by
depleting ERK5 levels in macrophages using transient small interfering
RNA (siRNA)–based knockdown in J774 cells (Fig. 1C) or tamoxifen-
inducible ERK5 gene loss in murine bone marrow–derived macro-
phages (Fig. 1D). In both cases, we were unable to achieve full loss of
the ERK5 protein (fig. S2), but this partial reduction in ERK5 level
nevertheless resulted in a reproducible enhancement of vomocytosis.
Thus, either pharmacological inhibition or genetic removal of ERK5
enhances vomocytosis in vitro.
Vomocytosis has been reported to occur with a wide range of live
phagocytic targets but has never been observed with inert particles or
dead pathogens. In line with this observation, pharmacological inhibi-
tion of ERK5 similarly enhanced vomocytosis of a second fungal1 of 8
SC I ENCE ADVANCES | R E S EARCH ART I C L Epathogen, Cryptococcus gattii, but despite extensive imaging we were
not able to observe any expulsion events for latex beads or heat-
inactivated cryptococci (Fig. 2A). Thus, ERK5 is acting as a suppressor
of the canonical vomocytosis pathway, rather than artificially inducing
expulsion of all phagocytic cargo.
The canonical ERK5 pathway involves ERK5 activation via the
upstreammitogen-activated protein (MAP) kinase MEK5 (15). Inhibi-Gilbert et al. Sci. Adv. 2017;3 : e1700898 16 August 2017tion of MEK5 with the specific inhibitor BIX02189 (16) similarly raised
vomocytosis levels in macrophages (Fig. 2B), suggesting that vomocy-
tosis rates are normally suppressed by the MEK5-ERK5 signaling axis.
To test this possibility further, we exposed cells to insulin-like growth
factor 2 (IGF2),whichhaspreviously been shown to activateMEK5-ERK5
signaling up to eightfold (17) and to be implicated in phagocyte be-
havior (18). In line with this, IGF2 stimulation reduced cryptococcalFig. 1. Pharmacological or genetic inhibition of ERK5 enhances vomocytosis in vitro and ex vivo. (A) Vomocytosis is enhanced in J774.A1 cells by the LRRK2
inhibitor LRRK2-IN-1 (1 mM) but not by a second LRRK2 inhibitor, HG1010201 (1 mM). Vomocytosis is more strongly enhanced by specific inhibition of ERK5 (an off-target
of LRRK2-IN-1) by XMD17-109 (1 mM) but not by inhibition of a second off-target, BRD4, by the inhibitor JQ1 (1 mM). Dual application of LRRK2-IN-1 and XMD17-109 (1 mM of
each) showed significant enhancement of vomocytosis that was not significantly different to that of XMD17-109 alone. ns, not significant. (B) Application of 1 mM XMD17-109
to human PBMC-derived macrophages also significantly enhances vomocytosis rates in vitro. (C) Partial knockdown of ERK5 expression in J774.A1 by siRNA enhances
vomocytosis. (D) Tamoxifen-inducible reduction of ERK5 expression ex vivo in murine bone marrow–derived macrophages significantly raises vomocytosis rates. Statistical
significance was tested by c2 using a Bonferroni correction for multiplicity. All data represent pooled, averaged data from three to nine experimental repeats, with error bars
showing the SEM. Example movies used for scoring are shown in movies S1 and S2.2 of 8
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or genetic inhibition of the ERK5 pathway enhances vomocytosis,
and indirect stimulation of the pathway via IGF2 suppresses it.
Macrophage behavior is strongly influenced by the local concen-
tration of cytokines, released both by themselves and by other cell
types. In particular, different cytokine environments can modulate
macrophage activation states (19), and we and others have previ-
ously shown that altered macrophage polarization states modify
vomocytosis rates (20). We therefore considered whether ERK5
might regulate vomocytosis by modifying macrophage polarization
and the local cytokine environment.
To determine the impact of ERK5 on macrophage polarization, we
assessed the expression of surface markers on J774 macrophages ex-
posed to XMD17-109. At rest, macrophages express both the pro-Gilbert et al. Sci. Adv. 2017;3 : e1700898 16 August 2017inflammatory marker CD86 and the anti-inflammatory marker MGL
but are efficiently polarized to CD86hi (M1-like) cells when exposed to
exogenous interferon-g (IFN-g) and lipopolysaccharide (LPS) or con-
versely to MGLhi (M2-like) cells upon exposure to interleukin-4 (IL-4)
(Fig. 3A). Cells treated with XMD17-109 showed no change in the ex-
pression of CD86 markers (Fig. 3A, i) either at rest or stimulated with
IFN-g and LPS. In contrast, XMD17-109 treatment strongly reduced
the expression of MGL both in resting cells and in cells polarized by
exposure to IL-4 (Fig. 3A, ii). Thus, ERK5 inhibition in macrophages
leads to amodified inflammatoryprofile that prevents anti-inflammatory
polarization without modifying their response to inflammatory stimuli.
To determine the consequence of this modified inflammatory
profile, we performed enzyme-linked immunosorbent assay (ELISA)
analysis to quantify secreted cytokine levels in supernatants frommouseFig. 2. Modulation of the canonical ERK5 signaling pathway alters vomocytosis rate but does not induce expulsion of inert phagosomal cargo. (A) ERK5
inhibition enhances vomocytosis of both C. neoformans and C. gattii but does not induce vomocytosis of heat-killed cryptococci or inert 3-mm polycarbonate beads.
Numbers above each column represent the total number of individual fungal cells or beads scored. (B) Inhibition of MEK5 activity (an upstream regulator of ERK5) with
3 mM BIX02189 recapitulates the enhancement of vomocytosis seen with ERK5 inhibition in J774 macrophages, whereas stimulation of the ERK5 pathway via 1 mM IGF2
significantly reduces vomocytosis rates. Statistical significance was tested by c2 on raw data from three independent repeats. Error bars represent the SEM.3 of 8
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Fig. 3. ERK5 inhibition suppresses M2 macrophage polarization, alters secreted cytokine profiles, and modifies the actin cytoskeleton. (A) (i) Pharmacological
inhibition of ERK5 with XMD17-109 does not alter expression of the M1 macrophage marker CD86 in J774 macrophages at rest or under M1 (LPS and IFN-g) or M2 (IL-4)
stimulating conditions. (ii) However, IL-4–driven M2 polarization is strongly reduced in the presence of XMD17-109. Significance was tested using two-way analysis of
variance (ANOVA) on data from three independent replicates. Error bars show the SEM. (B) XMD17-109 inhibition of ERK5 activity in J774 macrophages increases
proinflammatory IL-12p40 secretion (i) while reducing the secretion of the M2 marker Ym1 (ii). Significance was tested using a ratio-paired t test. (C) XMD17-109
inhibition of ERK5 activity in human PBMC-derived macrophages increases proinflammatory TNFa secretion (i) while reducing the secretion of the anti-inflammatory
cytokine IL-10 (ii). Significance was tested using a ratio-paired t test. (D) J774 macrophages treated with XMD17-109 show a reduction in actin ruffles (revealed using
Alexa 488–phalloidin; i). (ii) Ruffle disruption by XMD17-109 results in increased numbers of smaller actin-rich fragments, quantified in binary images (n = 33 images
from n = 3 replicates, two-tailed t test; error bars are SEM). Images were captured using identical illumination, exposure, and postacquisition processing settings.Gilbert et al. Sci. Adv. 2017;3 : e1700898 16 August 2017 4 of 8
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(Fig. 3C) treated with XMD17-109. In line with the reduction in IL-4
polarization induced by ERK5 inhibition, both cell types showed an
increased secretion of proinflammatory cytokines [IL-12p40 or tumor
necrosis factor–a (TNFa)] and a reduced secretion of M2-associated
proteins (Ym1 or IL-10) upon exposure to XMD17-109.
ERK5 has previously been implicated in cytoskeletal remodeling
(21, 22), and previouswork has shown thatmild inhibition of phagocyte
actin dynamics triggers enhanced vomocytosis (23). We therefore fixed
J774 cells exposed to C. neoformans in the presence or absence of
XMD17-109 and stained for filamentous actin. ERK5 inhibition did
not lead to any gross alteration of the actin cytoskeleton, in line with
our observation that XMD17-109 does not alter phagocytosis rates or
cell motility (both actin-driven processes). However, we noted a subtle
reduction in the number and size of actin-rich ruffles in treated cells,
suggestive of a slight destabilization of actin filamentation during
ERK5 inhibition (Fig. 3D). Thus, the impact of ERK5 inhibition
on vomocytosis likely results from a combination of reduced M2 in-
flammatory signaling and a diminished ability to constrain cryptococci
within filamentous actin “cages.”
Vomocytosis was first observedmore than a decade ago (1, 2), but an
enduring open question in the field has been whether it serves to in-
crease or reduce pathogenesis in infected organisms. Although in vivo
vomocytosis has been implied indirectly (4), it is only very recently thatGilbert et al. Sci. Adv. 2017;3 : e1700898 16 August 2017extended imaging in the zebrafish model has provided direct evidence
for its occurrence within a living animal (6, 24).
We exploited this model to explore the impact of modifying vomo-
cytosis rates on cryptococcal disease progression.We infected zebrafish
larvae in the presence of XMD17-109 or a dimethyl sulfoxide (DMSO)
control and then used extended live-cell imaging of anesthetized fish to
quantify vomocytosis in vivo. As with our in vitro studies, ERK5 inhi-
bition led to significantly enhanced vomocytosis rates in vivo (Fig. 4A).
However, although the overall fungal burden at day 3 after infection did
not differ significantly between control and inhibitor-treated fish, ERK5
inhibition led to a significant decrease in disease dissemination from the
initial point of infection (Fig. 4B). In humans, cryptococcal dissemina-
tion from the lung (the initial point of entry) to other tissues (in partic-
ular, the central nervous system) is thought to depend, at least in part,
on “Trojan Horse” transportation within host phagocytes (25). Thus,
elevating vomocytosis rates presumably reduces dissemination by trig-
gering phagocytes to eject their fungal cargo before they migrate far
from the initial site of infection.DISCUSSION
Together, these findings identify ERK5 as the first cellular signaling
component to regulate vomocytosis. There are a number of ERK5
inhibitors under clinical development (15), and further work is neededDMSO Erk5 inhbitior
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Fig. 4. ERK5 inhibition enhances vomocytosis and reduces dissemination in a zebrafish model of cryptococcosis. (A) Infected zebrafish treated with XMD17-109
show a significant (P = 0.001, Fisher’s exact test) increase in vomocytosis in vivo over 24 hours. Bars represent the median and 5th/95th percentile. (B) Overall fungal
burden at 3 days after infection is not significantly altered by ERK5 inhibition. Bars represent the median and 5th/95th percentile, with the boxed region representing
the interquartile range. (C) Individual infections can be individually scored as nondisseminated (restricted to the bloodstream; top), disseminated to muscle/tissue
blocks (middle), or disseminated to the central nervous system (bottom). CNS, central nervous system. (D) Infected fish treated with XMD17-109 show significantly
(P < 0.05, Fisher’s exact test) reduced dissemination from the site of infection. Bars represent the median and 5th/95th percentile.5 of 8
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value. However, we note that the ERK5 locus is polymorphic in humans
and that specific polymorphisms have been linked to lung cancer risk in
smokers (26) and thus variation in ERK5 activity may contribute to the
significant individual variation in vomocytosis rate between healthy
donors and, consequently, to the risk of disseminated cryptococcosis.MATERIALS AND METHODS
All reagents and media were purchased from Sigma-Aldrich, unless
specified otherwise.
Cryptococcus strains
Strains used wereC. neoformans var. grubii serotype Awild-type strains
H99 or KN99, green fluorescent protein (GFP)–expressing derivatives
KN99-GFP or H99-GFP, and C. gattii serotype B R265 or its GFP-
expressing derivative R265-GFP (27). These were grown overnight in
yeast peptone dextrose broth (2% glucose, 1% peptone, and 1% yeast
extract) at 25°C on an orbital rotator (20 rpm).
J774A.1 cell culture
J774A.1 murine macrophages were cultured at 37°C in 5% CO2 in
complete Dulbecco’s modified Eagle medium (DMEM) with 2 mM
L-glutamine, streptomycin (100 U/ml) and penicillin (0.1 mg/ml),
and 10% fetal bovine serum (FBS) and passaged when confluent by
scraping and resuspension in fresh medium.
Human primary macrophage isolation and culture
Allworkwithhuman tissuewasapprovedby theUniversityofBirmingham
Ethics Committee under reference ERN_10-0660. Twenty to fortyml of
blood was withdrawn from healthy volunteers by venipuncture and
diluted twice in cold phosphate-buffered saline (PBS) before layering
on top of 20 ml of Ficoll-Paque. Samples were centrifuged at 400g for
30 min at 20°C without braking in a swing bucket rotor. The white
disc of peripheral blood mononuclear cells (PBMCs) obtained was
washed twice in cold PBS (harvesting cells in between by centrifuga-
tion at 300g for 10 min), resuspended in PBS, counted, and then plated
onto multiwell dishes in RPMI 1640 with 10% FBS and granulocyte-
macrophage colony-stimulating factor (50 ng/ml).
Murine bone marrow–derived macrophage isolation
and culture
Mice carrying the erk5F allele and the CMV-CreER transgenes were
identified by polymerase chain reaction (PCR) on genomic DNA, as
previously described (28). The colony was maintained in a pathogen-
free facility at the University of Manchester, and all animal procedures
were performed under license in accordance with the UKHome Office
Animals (Scientific Procedures) Act 1986 and institutional guidelines.
Primary macrophages were obtained from bone marrow cells isolated
from femurs of genetically modified mice and cultured in DMEM
containing 10% FBS, 1% penicillin/streptomycin, and 20% L929 cell-
conditioned medium as a source of CSF-1 (colony-stimulating factor–1).
Where indicated, the cells weremock-treatedwithDMSOor incubated
with 4-hydroxytamoxifen (4-HT; 0.1 mM) at day 5 to induce Cre-
mediated recombination of the erk5F allele.
In vitro infection and imaging
Fungi were opsonized with pooled humanAB serum for 1 hour at 37°C
and 5%CO2 before infection.Macrophages were exposed to fungal cellsGilbert et al. Sci. Adv. 2017;3 : e1700898 16 August 2017at a multiplicity of infection of 10:1 for 2 hours, with or without the
addition of inhibitors or DMSO controls. Extracellular fungi were
removed by washing with fresh medium, containing inhibitors or
DMSO control, and maintained under these conditions for 18 hours
of time-lapse imaging. Time-lapsemoviesweremade using aTi-ENikon
or Zeiss AxioObservermicroscope. Samples were incubated at 37°C and
5%CO2 in themicroscope imaging chamber. Images were taken every
5 min for 18 hours and compiled into single movie files for analysis
using NIS Elements or Zeiss Zen software, respectively. Movies were
blinded by a third party before manual scoring for vomocytosis and
macrophage integrity. Vomocytosis was scored visually using the
following preagreed guidelines:
(1)One vomocytosis event is the expulsionof internalized cryptococci
from an infected macrophage, regardless of the number of cryptococci
expelled if they do so simultaneously.
(2) Vomocytosis events are scored as independent phenomena if
they occur in different frames or from different macrophages.
(3) Vomocytosis events are discounted if the host macrophage sub-
sequently undergoes lysis or apoptosis within 30 min.
For fixed cell imaging, cells were plated onto glass coverslips and
then infected as above before fixing with 4% paraformaldehyde in
PBS (10 min) and then staining with Alexa 488–phalloidin (20 min).
Coverslips were mounted onto glass slides using ProLong Antifade
and imaged on a Zeiss Axio Observer.
ERK5 siRNA
Accell Mouse MAPK7 (ERK5)–SMARTpool siRNA was purchased
from Dharmacon GE Healthcare and used according to the manufac-
turer’s instructions. J774A.1 murine macrophages (5.0 × 103) were
seeded into a 96-well plate and incubated at 37°C and 5% CO2 in a
humidified incubator for 24 hours. SMARTpool siRNA, or a scrambled
siRNA control, was applied at 1 mMper well, incubated at 37°C and 5%
CO2 in a humidified incubator for 96hours, and then infected and time-
lapse–imaged as described above.
Secreted cytokine quantification
DuoSet ELISA Development kits from R&D Systems were used for all
cytokine quantification and used according to the manufacturer’s in-
structions. Secreted murine Ym1 was detected by sandwich ELISA
using anti-Ym1 antibody (Abcam). Media supernatants from infected
macrophages, treated with XMD17-109 or DMSO for 18 hours, were
serially diluted before ELISA analysis and cytokine concentrations
derived by reference to a standard curve.
Polarization assays
J774 macrophages were seeded at 0.2 × 106 cells per well in DMEM
containing 10% heat-inactivated FBS and then stimulated with IL-4
(20 ng/ml) (ImmunoTools) or LPS (20 ng/ml) (Sigma-Aldrich) +
1000 IU IFN-g (ImmunoTools), in the presence or absence of 1 mM
XMD17-109. After 24 hours, the cells were placed on ice and stained
for viability and macrophage activation markers (LIVE/DEAD Aqua
Thermo, CD11b-BV605 BD, MGL-PE BioLegend, and CD86-FITC
BD). Events were acquired using an Attune flow cytometer, and data
were analyzed using FlowJo 8.7.
Statistical analysis
Statistical analysis was performed using a combination of Microsoft
Excel, GraphPad Prism, MaxQuant (mass spectrometry tools), and
the statistical program R, together with the online software DAVID6 of 8
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to detect significant enrichment of gene ontology clusters (29).
Zebrafish
Animal work was carried out per guidelines and legislation set out in
UK law in the Animals (Scientific Procedures) Act 1986, under Project
License PPL 40/3574. Ethical approval was granted by the University of
Sheffield Local Ethical Review Panel. We used the Nacre as our wild-
type strain.We used themacrophage Tg(mpeg1:mCherryCAAX)sh378
fluorescent transgenic zebrafish line (6). Zebrafish strains were main-
tained according to the standard protocols. Adult fish were maintained
on a 14:10-hour light/dark cycle at 28°C in UKHomeOffice–approved
facilities in the Bateson Centre aquaria at the University of Sheffield.
Zebrafish were infected as described previously (6) with 500 colony
forming units of Cryptococcus strain KN99-GFP. For time-lapse imag-
ing, zebrafish larvae were mounted in 0.8% low–melting point agarose
in E3 containing tricaine (0.168mg/ml). Imageswere capturedwithCFI
Plan Apochromat l [20×; numerical aperture (NA), 0.75 objective lens;
10 z-sections 2.5 mm apart], with Perfect Focus system, every 2 min for
12hours. For co-infection studies,weusedH99-GFP (27) andH99-dsRed
(30). For fungal burden and dissemination imaging, zebrafish were im-
aged in 96-well plates usingNikon Ti-E with a CFI Plan Achromat UW
(2×; NA, 0.06 objective lens), using Intensilight fluorescent illumination
with ET/sputtered series fluorescent filters 49002 (Chroma). Images
were captured with Neo sCMOS (Andor) and NIS Elements (Nikon).
Images were exported as tif files, and further analysis was performed in
ImageJ (31), as described previously (6).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/8/e1700898/DC1
table S1. Screened inhibitors of macrophage-expressed kinases.
fig. S1. Pharmacological inhibition of the MEK5/ERK5 signaling pathway does not alter
cryptococcal growth in vitro.
fig. S2. Quantification of ERK5 depletion in macrophages.
movie S1. Example time-lapse movie showing vomocytosis from J774 cells infected with H99-GFP
cryptococci and treated with DMSO (control).
movie S2. Example time-lapse movie showing vomocytosis from J774 cells infected with H99-GFP
cryptococci and treated with 1 mM XMD17-109.REFERENCES AND NOTES
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